Since the first line therapy for many breast cancer patients involves depleting peripheral estrogen production, it may be worth reconsidering how the tumor environment maintains ER activation through non-classical mechanisms, and whether this occurs more frequently in the context of poor metabolic health. Here, ESR1 is linked to neoplasm.